Rocket Stocks

[User-65225]

The street put this out on CVM this AM...

http://www.thestreet.com/_yahoo/story/10606428/1/biotech-mailbag-cel-sci-bioelectronics.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA

And the CEO followed up with this...lol... Oh my!...

Opinion: "Adam Who?"
Written by M.E.Garza
Friday, 02 October 2009 04:15


The following is my own opinion and not the opinion of any of the news organizations, syndicates, publishers or others who distribute this "penny pumping" content. At least, not on the record.

Does anyone still buy that garbage known as "The BioTech Mailbag" that TheStreet.Com's Adam Feuerstein writes? If so, why? When was the last time anyone made any good investment decisions based on the fallacious bunk that guy publishes? Seriously!

The failed fund manager, turned writer uses it as a platform to launch personal attacks at anyone who disagrees with him or thinks that he has a personal (or financial) agenda against him.

Isn't it long time that you come clean Mr. Feuerstein?

Come out from behind the veil of constitutionally protected free speech and start taking responsibility for some of the mistakes and millions you've caused companies and investors to lose.

Let's start with the biotech stock of the year, DNDN. Didn't you warn your readers to stay away from it with every last bit of electronic ink you could find?
Now you talk about them as if you were always on the bandwagon. Sorry. You weren't.

You called that, and just about every other low-cap biotech play that has made investors money all kinds of names in an attempt to shake weak hands and drop the stock price for the purposes of: a) letting your buddies short the stock b) letting your buddies buy shares at suddenly discounted rates c) profiting from the price action yourself d) basking in the pleasure of simply being able to do it because you're a short little bald guy who would otherwise have no power in the real world- except perhaps at some obscure town hall meeting standing up to yell at someone- might call some attention to yourself e) all of the above.

We find it odd that you launch your attacks, almost without fail, right after volume goes up and just before the stock's price goes up. Random chance? Don't buy it.

Maybe the most simple explanation is that he's in the pockets of big pharma since his favorite targets always seem to be the little guy biotechs that are not only shaking up the establishment, but making money (big money) for their investors along the way? Or perhaps, as one of his former co-workers told me it's all about calling attention to himself. "They write to the short side because it's all about controversy. The more controversy the more subscriptions they sell."

Don't let this popycock peddler with the poorest track record on the street (literally and figuratively) fool you.

His latest targets?

Cel-Sci, BioElectronics and BioMedReports. Read the fake mailbag letters and questions here.

Cel-Sci is called a media pumped stock and "an over-and-done drug company." I guess the FDA (who just fast tracked the company's H1N1 flu treatment) is in on the whole promotional scheme? Not to mention the Wall Street Journal- who quoted the investigative work in this space. When was the last time the Wall Street Journal quoted Adam Feuerstein's work? When we called them with the same question and their answer said it all: "Adam who?"

Adam still has no clue what the science behind BioElectronics is about or why companies like Kimberly Clark have taken an interest in what he describes as "magnets embedded in a bandage to reduce pain and swelling."

I'll never forget sitting behind Mr. Feuerstein at the recent Rodman & Renshaw conference and watching him and a sidekick intensely monitoring Level 2 trading on a laptop before attacking one of the presenters behind the podium during the time allotted for investors (not media members with their own agenda) to ask questions. What's with the engrossing level two interest in the trading action, anyway?

Perhaps that's one reason, among others, that investigative bodies like FINRA have taken an interest in his penmanship? Yes. That's true.

We can't say the same here.

As a matter of fact, we rarely have the same opinion about stocks and their underlying bio-technologies.

Maybe it's because we actually pick up the phone to ask questions of CEOs, patients and medical experts when we write stories and present opinions?

Yes. Mr. Feuerstein does "get it" sometimes- and yes, there are even times when he asks questions worthy of responses, but even a broken clock is right twice a day.

Good luck to anyone who invests their hard earned cash based on the opinions of Adam Feuerstein.

They'll need it.

Look. As humans, we all get it wrong sometimes.

Have your people call my people, Adam. Let's do lunch!

I'll be happy to recommend a few good journalism courses, oh and perhaps before we meet you can have your editors put all those published where you called it wrong back up on the website?

It should all be about a solid track record, after all, shouldn't it?

Disclosure: long on just about everything Adam suddenly bashes



BiomedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.